US › Healthcare

Sutro Biopharma (STRO)

US · Healthcare · Biotechnology

$25.67+2.27%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$14.5M
Revenue YoY
-16.5%
Net profit
$-38.5M
Profit YoY
+49.3%
EPS
$-2.94
EPS estimate
$-3.21
Net margin
-265.0%

EPS came in at -2.94 against a street estimate of -3.21 — a beat of 8.4%.

Key statistics

Market cap
$400.5M
Forward P/E
10.0
P/B
2.11
Book value
$-4.04
EPS (TTM)
$-16.35
52-week high
$43.85
52-week low
$7.15
50-day MA
$27.64
200-day MA
$20.71
Beta
1.52

Analyst view

Analysts rate Sutro Biopharma a buy (4 buy, 5 hold, 1 sell out of 10) with an average price target of $47.75.

Shareholding

Insiders
2.26%
Institutions
88.24%

Largest institutional holders

FundStake
Bvf Inc7.55%
Affinity Asset Advisors, LLC6.45%
Samsara BioCapital, LLC6.41%
Kynam Capital Management, LP5.27%
Orbimed Advisors, LLC4.83%
Vanguard Capital Management, LLC4.35%
Eventide Asset Management, LLC4.32%
Perceptive Advisors LLC4.32%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Sutro Biopharma — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.